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Rnd3 haploinsufficient mice are predisposed to
hemodynamic stress and develop apoptotic
cardiomyopathy with heart failure
X Yue1,6, X Yang1,6, X Lin1, T Yang1, X Yi2, Y Dai1, J Guo3, T Li3, J Shi4, L Wei4, G-C Fan5, C Chen1 and J Chang*,1
Rho family guanosine triphosphatase (GTPase) 3 (Rnd3), a member of the small Rho GTPase family, has been suggested to
regulate cell actin cytoskeleton dynamics, cell migration, and apoptosis through the Rho kinase-dependent signaling pathway.
The biological function of Rnd3 in the heart is unknown. The downregulation of small GTPase Rnd3 transcripts was found in
patients with end-stage heart failure. The pathological significance of Rnd3 loss in the transition to heart failure remains
unexplored. To investigate the functional consequence of Rnd3 downregulation and the associated molecular mechanism, we
generated Rnd3þ / haploinsufficient mice to mimic the downregulation of Rnd3 observed in the failing human heart. Rnd3þ /
mice were viable; however, the mice developed heart failure after pressure overload by transverse aortic constriction (TAC).
Remarkable apoptosis, increased caspase-3 activity, and elevated Rho kinase activity were detected in the Rnd3þ /
haploinsufficient animal hearts. Pharmacological inhibition of Rho kinase by fasudil treatment partially improved Rnd3þ /
mouse cardiac functions and attenuated myocardial apoptosis. To determine if Rho-associated coiled-coil kinase 1 (ROCK1) was
responsible for Rnd3 deficiency-mediated apoptotic cardiomyopathy, we established a double-knockout mouse line, the Rnd3
haploinsufficient mice with ROCK1-null background (Rnd3þ / /ROCK1 / ). Again, genetic deletion of ROCK1 partially but not
completely rescued Rnd3 deficiency-mediated heart failure phenotype. These data suggest that downregulation of Rnd3
correlates with cardiac loss of function as in heart failure patients. Animals with Rnd3 haploinsufficiency are predisposed to
hemodynamic stress. Hyperactivation of Rho kinase activity is responsible in part for the apoptotic cardiomyopathy
development. Further investigation of ROCK1-independent mechanisms in Rnd3-mediated cardiac remodeling should be the
focus for future study.
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Rho family guanosine triphosphatase (GTPase) 3 (Rnd3),
also called RhoE, is a member of the Rho family of GTPases.
The Rho family proteins belong to the Ras superfamily of
GTPases. Rnd3 was first identified as a member of the Rnd
subfamily by Jeffrey Settleman’s lab.1 Anne Ridley’s group
first suggested that Rnd3 functions as a Rho-associated
coiled-coil kinase 1 (ROCK1) but not ROCK2 inhibitor.2 The
current knowledge about the biological functions of Rnd3 has
beenmainly achieved by in vitro cell culture studies and tissue
screening assays. Rnd3 binds to ROCK1 to inhibit ROCK1
downstream targets, including myosin light-chain phospha-
tase, myosin light chain,3–5 and LIM kinase,6,7 which are
mainly involved in the regulation of cell actin cytoskeleton
dynamics, cell migration, and apoptosis.2,6–9
Apoptotic cardiomyopathy is characterized by loss of
cardiomyocytes, dilation of the chambers, and infiltration
and maturation of fibroblasts. Apoptosis along with the
activation of caspase-3 was found in the myocardium of
end-stage heart failure patients.10–13 Although, levels of
apoptosis detected in the failing heart are variable,10,14,15 a
low prevalence of apoptosis is sufficient to cause cardiac
contractile depression.16 Several transgenic animal models
have demonstrated that apoptotic myocyte death is a
determining factor involved in the transition to failure.16–20
The knowledge of biological functions of Rnd3 in vivo is
limited. Two recent mouse studies revealed an indispensable
role of Rnd3 in mouse neuron development.21,22 Using a
genetic deletion ofRnd3 approach, we further found that Rnd3
deficiency led to mouse hydrocephalus development.23 In this
study, we extend our mouse investigation to explore the
biological function of Rnd3 in the heart, which has not been
studied. A significant decrease in the Rnd3 mRNA levels was
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detected in the failing humanmyocardia in an early microarray
screening study (Profile GDS651/212724_at/RND3 in NCBI
GEO profiles). The etiologic meaning of Rnd3 downregulation
in the failing human heart is unknown. The investigation of this
downregulation has obvious clinical significance. To elucidate
the pathological significance of Rnd3 downregulation in the
heart, we established a patient-relevant mouse model,
Rnd3þ / haploinsufficient mice. The haploinsufficient
Rnd3þ / mice were viable and survived to adulthood without
obvious abnormalities compared to the wild-type (WT)
animals under physiological conditions. However, these mice
developed heart failure with apoptotic cardiomyopathy after
the mice were exposed to pressure overload. Treatment by
Rho kinase inhibitor or genetic deletion ofROCK1 rescued the
mouse apoptotic phenotype with partial improvement of
cardiac functions. We conclude that the mice with Rnd3
haploinsufficiency are predisposed to hemodynamic stress
partially due to the enhanced Rho kinase activity. Our study
suggests that the downregulation of Rnd3 is a risk factor in the
heart, and the manipulation of Rnd3 expression could be a
potential therapeutic target in human heart failure treatments.
Results
The Rnd3þ / haploinsufficient mice are predisposed to
pressure overload and develop severe heart failure after
the transverse aortic constriction challenge. The Rnd3þ /
mice were viable without detectable abnormalities in heart
morphology compared to WT mice (Figure 1a, sham and
Supplementary Table 1). The cardiac functions evaluated by
echocardiography showed no significant differences between
the two groups of mice (Figure 1b, sham and Supplementary
Table 1). However, obvious heart enlargement and dilation of
ventricular chambers were observed in the Rnd3 haploinsuffi-
cient heart after hemodynamic stress by transverse aortic
constriction (TAC; Figure 1a, TAC). The ejection fraction (EF)
and fractional shortening (FS) in the haploinsufficient hearts
were dramatically decreased from 66.7 and 36.8% to 15.1 and
6.7%, respectively (Figure 1b). Consistent with the echo
analysis in the Rnd3þ / mice, the animal lung weight over
body weight (LW/BW) and the LW over tibia length (LW/TL)
were significantly increased (Figure 1c), indicating heart failure
development.
Significant increases in apoptosis and Rho kinase
activity in the Rnd3þ / haploinsufficient hearts
after TAC. To assess the Rnd3þ / failing animal hearts
induced by TAC, we conducted terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) staining and
immunoblot analysis for caspase-3. Significant amounts of
TUNEL-positive cells were observed in the Rnd3 haploin-
sufficient heart compared to the WT control heart (Figures 2a
and b). The higher caspase-3 activity was also detected in
the same cohort of the Rnd3þ / hearts when compared to
the WT controls (Figures 2c and d). Meanwhile, we evaluated
the Rho kinase activity in the mutant hearts by immunoblot-
ting for the phosphorylation of myosin phosphatase target
subunit 1 (MYPT1). Hyperphosphorylation of MYPT1 was
observed, indicating an elevated Rho kinase activity in the
Rnd3þ / hearts (Figures 2e and f).
Rnd3 deficiency is sufficient to induce apoptotic cardi-
omyopathy along with activation of Rho kinase
signaling. We recently demonstrated that the Rnd3 /
homozygous mice were embryonically lethal around E11.0.
The embryonic mice with Rnd3 deficiency developed heart
failure.24 To investigate if the Rnd3 deficiency directly leads
to apoptotic cardiomyopathy under physiological conditions,
we analyzed E10.5 Rnd3 / homozygous mouse hearts.
Significant amounts of TUNEL-positive cells and elevated
caspase-3 activity were observed in the Rnd3-null hearts
compared to the WT control hearts (Figures 3a–c). Hyper-
phosphorylation was detected in the two targets of ROCK1,
MYPT1 and myosin light chain 2 (MLC2), indicating an
increase in Rho kinase activity in the Rnd3-null hearts
(Figure 3d).
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Figure 1 Rnd3þ / haploinsufficient mice developed heart failure after
3-week TAC. (a) Representative pictures of whole animal hearts and their
hematoxylin and eosin staining sections. Enlarged ventricles were displayed
in the Rnd3þ / mutant hearts after TAC. (b) Significant decreases in the
cardiac EF and FS were detected in Rnd3þ / mice compared to the WT mice
after TAC. (c) Significant increases in LW over BW and LW over TL indicated
heart failure development in Rnd3þ / hearts by pressure overload. The
numbers in the columns represent the number of mice in each group.
Statistical significance was determined by one-way ANOVA followed by
Student–Newman–Keuls method. Data are means±S.D. Scale bar represents
1 mm. BW, body weight; EF, ejection fraction; FS, fractional shortening; LW, lung
weight; TAC, transverse aortic constriction; TL, tibia length; WT, wild-type
Rnd3, heart failure and rho kinase
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Heart failure and apoptotic cardiomyopathy are partially
rescued by treatment with Rho kinase inhibitor fasudil in
Rnd3þ / haploinsufficient mice. Rnd3 has been
suggested to function as a Rho kinase ROCK1 inhibitor.
Rnd3 haploinsufficient mice develop heart failure along with
elevated Rho kinase activity after pressure overload. To
explore a possible mechanism that Rnd3 downregulation-
mediated cardiac dysfunction is associated with increased
Rho kinase activity, we treated the Rnd3þ / mice with
fasudil, a clinically used Rho kinase inhibitor, immediately
after TAC. Three weeks later, significant improvements in
cardiac functions (Figure 4a) and less cardiac apoptosis
(Figures 4b and c) were observed in fasudil-treated mice
compared to non-treated animals. Cardiac EF and FS were
improved from 19.1 and 8.6% to 40.3 and 19.5%, respec-
tively (Figure 4a). The increases in caspase-3 activity
(Figures 4d and e) and Rho kinase activity (Figures 4f and g)
were also significantly eased. To rule out if the improve-
ment of cardiac phenotype was due to fasudil-mediated
vasodilation, mouse blood pressures were compared among
sham, TAC, and TAC plus fasudil groups in WT and
Rnd3þ / haploinsufficient mice. We found no significant
differences in blood pressures among the groups or between
WT and Rnd3þ / haploinsufficient mice, suggesting a
minimal effect of vasodilation on the cardiac improvement
(Supplementary Figure 1).
Although, the cardiac apoptosis and Rho kinase activity
returned to the control levels, levels of the improved cardiac
EF and FS were still significantly below the levels in sham
control mice (Figure 4a). The cardiac functional recoveries by
Rho kinase inhibitor treatment were partial, suggesting that
other factors besides Rho kinase activation contribute to Rnd3
deficiency-mediated cardiac dysfunction as well.
Genetic deletion of ROCK1 attenuates Rnd3 deficiency-
mediated apoptotic cardiomyopathy and improves
cardiac functions. To further investigate the role of ROCK1
activation in Rnd3 deficiency-mediated cardiomyopathy, we
created the Rnd3þ / with ROCK1-null background mouse
line, Rnd3þ / /ROCK1 / (Figure 5a). The double-knockout
mice showed normal cardiac EF and FS (Figure 5b, sham).
The Rnd3þ / mice and Rnd3þ / /ROCK1 / mice were then
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Figure 2 Rnd3þ / haploinsufficient mice were predisposed to hemodynamic stress. Severe cardiac apoptosis and Rho kinase activation were detected after TAC.
(a) Significant increases in TUNEL-positive cells were observed in Rnd3þ / hearts compared to WT control hearts after TAC. The arrows indicate TUNEL-positive cells
(green) overlapped with nucleus counter-staining (blue). Cardiomyocytes were visualized by red fluorescent staining for F-actin. Scale bar represents 10mm. (b) Quantification
of the TUNEL-positive cells in mouse hearts. Statistical significance was determined by one-way ANOVA followed by Student–Newman–Keuls method. Data are
means±S.D. (c) Higher caspase-3 activities were detected in Rnd3þ / hearts compared to WT animal hearts after TAC. (d) Densitometry analysis of active caspase-3
normalized by GAPDH. (e) Hyperphosphorylation of Rho kinase substrate MYPT1 exhibited in Rnd3þ / hearts indicates elevated Rho kinase activity compared to WT hearts
after TAC. (f) Densitometry analysis of MYPT1 phosphorylation. Statistical significance was determined by unpaired, two-tailed Student’s t-test. Data are means±S.D.
Casp3, caspase-3; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; MYPT1, myosin phosphatase target subunit; ROCK1, Rho-associated coiled-coil kinase 1;
TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling. The numbers in the columns represent the number of mice in each group
Rnd3, heart failure and rho kinase
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exposed to TAC stress for 3 weeks followed by cardiac
function analysis and cardiac apoptosis assessment. Again,
we observed a deteriorated cardiac function with EF 19.9%
and FS 8.9% in Rnd3þ / haploinsufficient mice after TAC.
However, double-knockout mice showed better cardiac
functions with EF 52.9% and FS 26.5% compared to
Rnd3þ / mice (Figure 5b, TAC). Less apoptotic cells and
attenuated caspase-3 activity were detected in double-knockout
mice compared to Rnd3þ / mice (Figures 5c–f), suggesting
that ROCK1 activation contributes to Rnd3 deficiency-mediated
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Figure 3 Complete deletion of Rnd3 gene resulted in severe apoptotic cardiomyopathy along with the elevation of Rho kinase activity in the mouse hearts. (a) A significant
amount of TUNEL-positive cells were displayed in E10.5 Rnd3-null hearts. The arrows indicate TUNEL-positive cells (green) overlapped with nucleus counter-staining.
Cardiomyocytes were visualized by red fluorescent staining for F-actin. NS indicates nonspecific staining. (b) Quantification of the TUNEL-positive cells in hearts. (c) Elevated
caspase-3 activity was detected in Rnd3-null hearts by immunoblot analyses and quantified by immunoblot densitometry analyses. (d) Elevated Rho kinase activity was
detected in Rnd3-null hearts by immunoblotting for two Rho kinase substrates, MYPT1 and MLC2. The immunoblot densitometry analyses were quantified. Statistical
significance was determined by unpaired, two-tailed Student’s t-test. Data are means±S.D. TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling;
MLC2, myosin light chain 2. The numbers in the columns represent the number of mice in each group
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Figure 4 Rho kinase inhibitor fasudil treatment partially improved Rnd3þ / mouse cardiac functions and attenuated apoptotic cardiomyopathy induced by 3-week TAC.
(a) Echocardiographic assessment of cardiac functions. (b) A comparison of TUNEL staining in Rnd3 haploinsufficient heart sections among three groups: Sham, TAC only,
and TAC plus fasudil treatment. The arrows indicate TUNEL-positive cells (green) overlapped with nucleus counter-staining. Cardiomyocytes were visualized by red
fluorescent staining for F-actin. Scale bar represents 10 mm. (c) Quantification of TUNEL staining among the hearts from the three groups. (d) Active and full-length of
caspase-3 expression levels among the three groups assessed by immunoblot. (e) Densitometry analysis of active caspase-3 normalized by GAPDH. (f) Phosphorylation
levels of Rho kinase substrate MYPT1 among the three groups assessed by immunoblot. (g) Densitometry analysis of MYPT1 phosphorylation. Statistical significance was
determined by one-way ANOVA followed by Student–Newman–Keuls method. Data are means±S.D. The number in each column represents the number of mice in the group
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apoptotic cardiomyopathy. However, consistent with Rho
kinase inhibitor fasudil treatment, genetic deletion of ROCK1
was not able to completely rescue Rnd3 deficiency-mediated
cardiac dysfunction (Figure 5b).
Discussion
The direct role of Rnd3 in the heart remains unexplored. The
current paradigm, derived from the majority of the published
studies on Rnd3, is that Rnd3 functions as an inhibitor of Rho
signaling by either directly binding to ROCK1 or indirectly
targeting RhoA through p190-B RhoGAP.2,8,25,26 Over-
expression of Rnd3 inhibited ROCK1-mediated biological
effects, and the reduced expression of Rnd3 potentiated
ROCK1 activity.2,8,27 Therefore, the functions of Rnd3 have
been almost entirely linked to cell actin cytoskeleton
dynamics, cell migration, and apoptosis demonstrated by
in vitro cell culture.2,6–9 Recently, emerging evidence starts to
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Figure 5 Genetic deletion of Rho kinase ROCK1 partially improved Rnd3þ / mouse cardiac functions and attenuated apoptotic cardiomyopathy induced by TAC.
(a) The genotyping profile showed the establishment of the double-knockout (DK) mouse line, Rnd3þ /ROCK1 / . (b) Echocardiographic assessment of cardiac functions.
(c) A comparison of TUNEL staining between the Rnd3þ / hearts and DK mouse hearts. The arrows indicate TUNEL-positive cells (green) overlapped with nucleus counter-
staining. Cardiomyocytes were visualized by red fluorescent staining for F-actin. Scale bar represents 10 mm. (d) The quantification of the TUNEL results between the two
groups of mouse hearts. (e) Active and full-length of caspase-3 expression levels between the two groups of mouse hearts assessed by immunoblot. (f) Densitometry analysis
of active caspase-3 normalized by GAPDH. Statistical significance was determined by one-way ANOVA followed by Student–Newman–Keuls method. Data are means±S.D.
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show that Rnd3 may be involved in the regulation of ERK and
p38 pro-survival pathway in U87 cells and keratinocytes;28,29
while in prostate cancer cell lines, the effect of Rnd3 on cell
apoptosis was associated with cell cycle regulation.30 Our
recent Rnd3 genetic mouse study demonstrated that Rnd3 is
a novel mediator that inhibits Notch signaling by facilitating the
ubiquitination of the Notch active isoform, NICD, in the mouse
brain. Genetic deletion of Rnd3 results in hyperactivation of
Notch signaling.23 The new biological function of Rnd3 was
supported by two recent studies showing an indispensable
role of Rnd3 in animal brain development.21,22 These
emerging cell and animal studies strongly suggest that Rnd3
has much broader biological functions than previously
thought, which are beyond the Rho signaling pathway.
In this study, we provide evidence to support this new
concept. We demonstrate that the integrity of Rnd3 gene
expression is critical in the heart in response to hemodynamic
stress. The downregulation of Rnd3 predisposes the animal
heart to pressure overload. We reveal that hyperactivation of
Rho kinase is part of the mechanisms responsible for Rnd3
deficiency-induced apoptotic cardiomyopathy. Pharmaco-
logical inhibition of Rho kinase or genetic silence of ROCK1
partially improves Rnd3þ / mouse cardiac function and
attenuates cardiac apoptosis. Further investigation of Rho
kinase-independent regulatory mechanism of Rnd3 in the
heart will provide a new strategy for heart failure treatment.
The pro-apoptotic effect of ROCK1 has been characterized in
our previous studies in mice as well as others in cell lines.31–34
By loss-of-function approaches, we and other groups found
that genetic deletion of the ROCK1 gene enhanced mouse
heart resistance against stress-induced cardiac apoptosis
and fibrosis, and preserved cardiac functions.35–38 In human
patients with end-stage heart failure, we found a significant
increase in Rho kinase activity in the failing myocardium. This
increase was directly associated with caspase-3-dependent
cleavage of ROCK1, which generated a constitutively active
Rho kinase subspecies. The truncated ROCK1 facilitated
caspase-3 activation and fibrotic gene upregulation, which led
to a feed-forward loop promotingmyocyte apoptosis and heart
failure.31,35
Rho kinase is a downstream mediator of RhoA, and is
believed to play a critical role in mediating the effects of RhoA
on stress fiber formation, smooth muscle contraction, cell
adhesion, membrane ruffling, and cell motility.27,39 Studies of
regulatory activation of ROCK1 discovered that Rnd3 inhibits
RhoA-mediated ROCK1 signaling by specifically binding to
ROCK1 but not ROCK2.2,8 Rnd3 is one of the Rnd subsets of
the Rho family proteins, and is the only endogenous ROCK1
antagonist found so far.26 In contrast to the canonical mode of
Rho family proteins, the Rnd subfamily members, including
Rnd1, Rnd2, and Rnd3, bind but do not hydrolyze GTP. They
are defective in GTPase activity even in the presence of
RhoGAPs.1,40–42 Limited data on the biological effect of Rnd3
on ROCK1 have been obtained via the gain- and loss-of-
function approaches in vitro. Overexpression of Rnd3
inhibited ROCK1-mediated biological effects, including stress
fiber formation, phosphorylation of myosin light-chain phos-
phatase, and apoptosis. Reduced expression of Rnd3
promoted cell apoptosis by potentiating ROCK1 activity.2,8,27
The antiapoptotic effect of Rnd3 was observed in response to
genotoxic stress;8 chemotherapeutic agents or ultraviolet B
radiation-induced DNA damage in different cell lines.28,43
Reduced expression levels of Rnd3 in different cancers were
observed, and were proposed to associate with tumor
invasion, apoptosis, and metastasis.30,44–46
Fasudil is the only clinically available Rho kinase inhibitor,
and it has been in clinical use as an antivasospasm agent in
Japan since 1995. Several clinical trials have demonstrated
that fasudil increased forearm blood flow in hypertensive
patients,47,48 attenuated patients’ coronary artery spasms,49
improved coronary microcirculation,50 and increased the
ischemic threshold of angina patients during exercise with a
trend toward increased exercise duration.51 Like any other
pharmacological inhibitors, the inhibitory effect of fasudil on
other protein kinases, such as PKA, has also been reported at
high dosage applications. To eliminate any potential side
effects of fasudil and to validate a direct involvement of
ROCK1 in Rnd3-mediated cardiomyopathy, ROCK-null back-
ground mice with Rnd3 haploinsufficiency were introduced.
Consistent with the Rho kinase treatment result, we found that
genetic loss of ROCK1 gene also partially attenuated
hemodynamic stress-induced cardiomyopathy in Rnd3 hap-
loinsufficient mice. The data provide definitive evidence that
Rho kinase activation is responsible in part for Rnd3
deficiency-induced cardiomyopathy.
The relationship between Rnd3 protein expression levels
and its significance in human heart failure remains unclear. A
downregulation of Rnd3 transcripts was reported in one failing
human myocardium microarray database. The pathological
consequence of the reduced Rnd3 mRNA in heart failure
patients is also unknown. We took advantage of the
haploinsufficient mice to investigate the pathological role of
Rnd3 downregulation in the animal. From this study, we
conclude that a lower expression level of Rnd3 is a deleterious
factor in the heart.
In summary, our study demonstrates an essential role of
Rnd3 for normal cardiac functions in mice. Genetic loss of
Rnd3 predisposes the animal heart to transition to failure.
Activation of Rho kinase signaling is partially responsible for
this maladaptive transition. Our findings provide a potential
alternative target for pharmacological manipulations in heart
failure treatment.
Materials and Methods
Generation and verification of Rnd3 knockout (KO) mice and
Rnd3 haploinsufficient with ROCK1-null double-knockout
Rnd3þ / /ROCK1 / mice (DK). The establishment of individual Rnd3
KO and ROCK1 KO mouse lines were described previously.23,36 We bred Rnd3
KO mice with ROCK1 KO mice to achieve Rnd3þ / /ROCK1 / DK mice. All
animal experiments were approved by the Institutional Animal Care and Use
Committee of the Texas A&M University Health Science Center-Houston.
TAC and fasudil treatment. TAC was conducted in 10–15-week-old adult
male mice. The thymus was retracted to expose the transverse aorta. Between the
right innominate and left carotid artery, an aortic constriction was achieved by tying
a 6-0 suture against a 3 mm length of 27 gauge needle. After two knots, the 27
gauge needle was promptly removed, which yielded a constriction ofB0.3 mm as
the outer diameter of the 27 gauge needle. The procedure imposed a 60–80%
aortic constriction on the animal. To minimize the variation of the constriction
among the animals, only the mice with a ratio of right-to-left carotid artery flow
velocity from 5 : 1 to 10 : 1 were used. The artery flow velocity was measured by a
Pulsed Doppler (Indus Instruments, Houston, TX, USA). As a control, a sham
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operation without occlusion was performed on age-matched littermate mice. For
the rescue experiment, mice were allowed access to drinking water containing
fasudil (B100mg/kg/day; LC Laboratories, Woburn, MA, USA) for 3 weeks
starting immediately after TAC surgery. All of the TAC-induced pressure overload
stress lasted for 3 weeks.
Cardiac function assessment by echocardiography and blood
pressure measurement. For cardiovascular measurements, a Vevo770
High-Resolution Micro-Imaging System (VisualSonics, Toronto, ON, Canada) with
30-MHz probe (RMV-707B) was used as previously described.35 Male mice were
anesthetized with 3–4% isoflurane, and then switched to 1–1.5% isoflurane mixed
with 100% oxygen. At the level of the papillary muscles, two-dimensional-guided
M-mode echocardiography was obtained from anterior (þ septum) and posterior
walls. Mouse systolic blood pressure measurement was recorded by Mouse Blood
Pressure System (MRBP-MMC, IITC Life Science Inc, CA, USA) through tail-cuff
method after the mouse was trained for 2–3 days until it was comfortable and quiet
in the nose cone animal holder. Mouse diastolic blood pressure was calculated by the
software MRBP Monitor Version 1.59 (MRBP-MMC, IITC Life Science Inc, CA, USA).
Immunoblotting, hematoxylin and eosin staining, and
fluorescence staining. Protein samples for western blot analysis were
extracted and separated as described previously.52 Commercially available
antibodies were from the following sources: MYPT1 (2634S), Phospho-T853
MYPT1 (4563S) from Cell Signaling Technology (MA, USA); MLC2 (PA5-17624),
Phospho-Thr18/Ser19 MLC (PA5-17727) from Thermo Scientific Pierce (IL, USA);
caspase-3 (sc-7148) from Santa Cruz Biotechnology (CA, USA). Equivalent
protein loading was verified by the intensity of the GAPDH blot.
Hearts were fixed using the Langendorff perfusion system (Radnoti, 120108).
Paraffin sections of the whole heart were used for hematoxylin and eosin staining
and TUNEL staining (In Situ Cell Death Detection Kit, 11684795910, Roche, USA).
Pictures were taken under the  40 microscope objective. A total of 20 staining
pictures from each group (3–8 mice) were quantified for TUNEL analysis by Leica
Application Suite Imaging Software (Version 4.0, Germany). F-actin and nuclei were
visualized by phalloidin conjugated to Alexa Fluor 594 (A12381, Life Technologies,
Grand Island, NY, USA) and DAPI staining, respectively. The images were acquired
by fluorescence microscopy.
Statistical analysis. Data are expressed as means±S.D. In multiple group
comparisons, one-way ANOVA followed by Student–Newman–Keuls method was
used. In two group comparisons, unpaired, two-tailed Student’s t-test was used. All
of the analyses were conducted by SigmaPlot 11.0 (Systat, San Jose, CA, USA).
A value of Po0.05 was considered statistically significant.
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